Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

Breast cancer is the fifth cause of cancer death among women worldwide and represents a
global health concern due to the lack of effective therapeutic regimens that could be applied …

In oncology, liquid biopsy is used in the detection of next-generation analytes, such as tumor
cells, cell-free nucleic acids and exosomes in peripheral blood and other body fluids from …

Introduction: In hormone receptor-positive breast cancer, ESR1 mutations have emerged as
a key mechanism of resistance to endocrine therapy. Areas covered: Here, we review …

Background Breast cancer has, due to its high incidence, the highest mortality of cancer in
women. The most common molecular type of breast cancer is the luminal subtype, which …

Background Endocrine therapy is recommended as a first-line treatment for hormone
receptor-positive metastatic breast cancer (HR+ MBC) patients. No biomarker has been …

After nearly 20 years of research, it is now established that mutations within the estrogen
receptor (ER) gene, ESR1, frequently occur in metastatic breast cancer and influence …

BACKGROUND: ESR1 mutations are frequently detected in ER+ MBC, and have been
reported to be associated with endocrine therapy resistance. However, there are little …

In only few years, circulating tumor DNA (ctDNA) in breast cancer has moved from purely
fundamental research to nearby daily use for treatment selection and drug-resistance …

Endocrine therapy is the main treatment option for estrogen receptor-positive (ER+) breast
cancer (BC). Compared with other clinical subtypes, ER+ BC patients usually have a more …